{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:20:15Z","timestamp":1793064015051,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:21:07Z","timestamp":1749756067000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications"],"prefix":"10.1053","volume":"62","author":[{"given":"Kasper J.","family":"Croese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-0824","authenticated-orcid":false,"given":"Jesse M.","family":"Tettero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10393","key":"10.1053\/j.seminhematol.2025.06.004_bib0001","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"The Lancet"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.004_bib0003","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.06.004_bib0004","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0006","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.06.004_bib0009","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41409-020-01005-y","article-title":"Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT","volume":"56","author":"Nagler","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0012","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0013","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.06.004_bib0014","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.004_bib0016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ajcp\/aqw038","article-title":"Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia","volume":"145","author":"Ouyang","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0017","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.06.004_bib0018","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2023-181709","article-title":"The Laip-based-Dfn approach is superior in terms of useful MRD results as compared to the Laip approach after cycle II in acute myeloid leukemia","volume":"142","author":"Ngai","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.004_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2018.11.014","article-title":"Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: is multicentric MRD assessment feasible?","volume":"76","author":"Brooimans","year":"2019","journal-title":"Leuk Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cyto.b.22140","article-title":"Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/measurable residual disease detection","volume":"104","author":"Wang","year":"2023","journal-title":"Cytometry Part B: Clin Cytom"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.004_bib0021","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cyto.b.22144","article-title":"Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry","volume":"104","author":"Tettero","year":"2023","journal-title":"Cytometry Part B: Clin Cytom"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0022","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0024","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2018.205955","article-title":"Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia","volume":"104","author":"Ross","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0025","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0026","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0027","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","article-title":"Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia","volume":"32","author":"Rothenberg-Thurley","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0028","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0029","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"31","key":"10.1053\/j.seminhematol.2025.06.004_bib0031","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0032","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, As detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0033","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1053\/j.seminhematol.2025.06.004_bib0034","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease\u2013based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.004_bib0036","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"JsF","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0037","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable (\u2018minimal\u2019) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0038","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Sarah","year":"2017","journal-title":"Haematologica"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.004_bib0039","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.06.004_bib0041","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0042","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation\u2013specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.004_bib0043","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Max","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0044","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.004_bib0046","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML study group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.06.004_bib0047","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0048","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1Mutation: a study by the Acute leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0049","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.25355","article-title":"Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission","volume":"94","author":"Poir\u00e9","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.06.004_bib0051","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0052","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0053","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0054","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-023-00833-7","article-title":"NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia","volume":"13","author":"Li","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0056","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0057","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0058","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/10428194.2019.1686500","article-title":"Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia","volume":"61","author":"Shimomura","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0059","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/ijlh.13070","article-title":"The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation","volume":"41","author":"Wang","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0060","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0061","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ejh.12336","article-title":"Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation","volume":"93","author":"Bastos-Oreiro","year":"2014","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.06.004_bib0062","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.004_bib0063","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41375-024-02300-z","article-title":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","volume":"38","author":"McCarthy","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0064","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0066","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ajh.21879","article-title":"Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations","volume":"85","author":"Dvorakova","year":"2010","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0067","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3109\/10428194.2010.508822","article-title":"Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis","volume":"51","author":"Stahl","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.004_bib0068","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0069","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Christophe","year":"2016","journal-title":"Haematologica"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.004_bib0070","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing\u2013based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0071","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.06.004_bib0072","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Ebert BL. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0073","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0074","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.06.004_bib0075","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.004_bib0076","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD\u2013mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.004_bib0077","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0078","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.004_bib0079","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.3390\/cancers14153576","article-title":"Real-world experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and azacitidine","volume":"14","author":"Ong","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0080","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0081","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26698","article-title":"Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission","volume":"97","author":"Short","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0082","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000535463","article-title":"Test then erase? Current status and future opportunities for measurable residual disease testing in acute myeloid leukemia","volume":"147","author":"Blackmon","year":"2023","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.004_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00078","article-title":"Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission","volume":"1","author":"Versluis","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0084","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bmt.2016.308","article-title":"Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia","volume":"52","author":"Buccisano","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0085","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/bloodadvances.2024014767","article-title":"Pretransplant MRD does not seem to affect survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation","volume":"9","author":"Fraccaroli","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.004_bib0086","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1Mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.004_bib0087","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0088","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41409-024-02373-5","article-title":"Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT","volume":"59","author":"Al Hamed","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0089","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","article-title":"Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival","volume":"108","author":"Tettero","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0091","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26757","article-title":"Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia","volume":"98","author":"Stahl","year":"2023","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.004_bib0092","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0093","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0094","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-021-00471-x","article-title":"Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation","volume":"11","author":"Jentzsch","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0096","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0097","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0098","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis","volume":"10","author":"Chang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.04.020","article-title":"Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0101","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3324\/haematol.2015.129650","article-title":"Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation","volume":"100","author":"Natasha","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0102","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2021012411","article-title":"How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy","volume":"141","author":"Biederst\u00e4dt","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0104","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0105","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Bhagirathbhai","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.06.004_bib0107","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0108","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0109","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ajh.27087","article-title":"Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: roadmap from an ELN-DAVID expert panel","volume":"98","author":"Ravandi","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0111","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","article-title":"Venetoclax\u2013based low intensity therapy in molecular failure of NPM1-mutated AML","volume":"8","author":"Jimenez-Chillon","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.004_bib0112","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.06.004_bib0113","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.004_bib0114","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.004_bib0115","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.004_bib0116","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","article-title":"Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia \u2013 a FILO study","volume":"38","author":"Orvain","year":"2024","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.06.004_bib0117","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2024-199036","article-title":"Leukemic stem cell measurable residual disease (LSC MRD) status is a better predictor of relapse than multiparametric flowcytometric analysis in acute myeloid leukemia patients","volume":"144","author":"Mawalankar","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0118","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.06.004_bib0119","doi-asserted-by":"crossref","first-page":"9140","DOI":"10.1182\/blood-2022-165438","article-title":"Full spectrum 40-parameter single-tube flow cytometry analysis for longitudinal immunophenotyping and tracing of clonal heterogeneity in AML","volume":"140","author":"Van Der Meer","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cyto.a.24811","article-title":"A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia","volume":"105","author":"Fokken","year":"2024","journal-title":"Cytometry Part A"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0121","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41592-023-02042-3","article-title":"A practitioner\u2019s view of spectral flow cytometry","volume":"21","author":"Sharma","year":"2024","journal-title":"Nat Methods"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.004_bib0122","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0123","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.10432","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow","volume":"92","author":"Luca","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.004_bib0124","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2023.283520","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","volume":"109","author":"Dillon","year":"2024","journal-title":"Haematologica"},{"issue":"93","key":"10.1053\/j.seminhematol.2025.06.004_bib0126","doi-asserted-by":"crossref","first-page":"36613","DOI":"10.18632\/oncotarget.26400","article-title":"Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia","volume":"9","author":"Patkar","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.004_bib0127","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2018.04.017","article-title":"Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML","volume":"24","author":"Zhou","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.004_bib0128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2018.194712","article-title":"A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia","volume":"104","author":"Esther","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.004_bib0129","first-page":"3543","article-title":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.004_bib0130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes, Chromosomes and Cancer."},{"issue":"22","key":"10.1053\/j.seminhematol.2025.06.004_bib0131","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0132","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","article-title":"Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples","volume":"20","author":"Cloos","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.004_bib0133","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-17-2344","article-title":"Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients","volume":"24","author":"Greif","year":"2018","journal-title":"Clin Can Res"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.06.004_bib0134","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2024-207490","article-title":"Measurable residual disease detection of IDH1 or IDH2 mutations post but not prior to allogeneic hematopoietic stem cell transplantation show high prognostic relevance in patients with acute myeloid leukemia","volume":"144","author":"Jendro","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0135","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.06.004_bib0136","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2022-167837","article-title":"ALLG AMLM26 Phase 1B\/2 study investigating novel therapies to target early relapse and clonal evolution As pre-emptive therapy in AML (INTERCEPT): a multi-arm, precision-based, recursive, platform trial","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.004_bib0137","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","article-title":"Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study","volume":"59","author":"Yang","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.004_bib0139","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41409-022-01839-8","article-title":"Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT cellular therapy & immunobiology working party","volume":"58","author":"Santoro","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:29:20Z","timestamp":1765632560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000290"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}